Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Daxor Corp (DXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,534
  • Shares Outstanding, K 3,729
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -7,190 K
  • 60-Month Beta -0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.75 +6.21%
on 03/22/19
19.95 -37.44%
on 02/26/19
-6.02 (-32.54%)
since 02/22/19
3-Month
7.34 +70.14%
on 12/24/18
19.95 -37.44%
on 02/26/19
+4.55 (+57.38%)
since 12/21/18
52-Week
4.30 +190.23%
on 08/17/18
19.95 -37.44%
on 02/26/19
+1.09 (+9.57%)
since 03/22/18

Most Recent Stories

More News
Daxor Corporation to Exhibit at the Society of Hospital Medicine (SHM) Annual Conference 2019

Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be exhibiting at...

DXR : 12.48 (+1.13%)
Daxor Corporation Addresses and Corrects Erroneous Seeking Alpha Healthcare News Editor Article of March 20, 2019

Author incorrectly claimed, "The company's sole product is a blood volume analyzer called the BVA-100 but there does not appear to be any sales to date."

DXR : 12.48 (+1.13%)
Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019

Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Michael Feldschuh,...

DXR : 12.48 (+1.13%)
Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018

Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today filed a Form N-CSR disclosing its...

CHFS : 3.63 (-5.22%)
DXR : 12.48 (+1.13%)
New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation's Blood Volume Analyzer (BVA-100(R)) in Critical Care

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new research from the...

DXR : 12.48 (+1.13%)
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

New Research Abstracts Scheduled for Presentation on Daxor's BVA-100

DXR : 12.48 (+1.13%)
Daxor Corporation Appoints Guido Manzo, Vice President of Sales

Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Guido Manzo as Vice President of...

DXR : 12.48 (+1.13%)
Daxor Corporation Announces Acquisition of BVA-100(R) Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Aspirus Wausau Hospital...

DXR : 12.48 (+1.13%)
A New Study Published in The Annals of Thoracic Surgery: Daxor's BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the publication of new research utilizing the BVA-100 blood volume analyzer...

DXR : 12.48 (+1.13%)
Pre-Market Technical Scan on Medical Supplies Equities -- Daxor, Endologix, Glaukos, and Halyard Health

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on DXR, ELGX, GKOS, and HYH which can be accessed for free by signing up to www.wallstequities.com/registration....

HYH : 57.25 (+0.07%)
ELGX : 6.71 (-6.42%)
GKOS : 80.10 (-0.55%)
DXR : 12.48 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade DXR with:

Business Summary

Daxor Corporation is a medical device manufacturing corporation with additional biotech services.

See More

Key Turning Points

2nd Resistance Point 13.69
1st Resistance Point 13.08
Last Price 12.48
1st Support Level 11.81
2nd Support Level 11.15

See More

52-Week High 19.95
Fibonacci 61.8% 13.97
Last Price 12.48
Fibonacci 50% 12.13
Fibonacci 38.2% 10.28
52-Week Low 4.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar